Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

Phase 2 Completed 15 enrolled University of British Columbia International Collaboration on Repair Discoveries · collab Pfizer · collab Vancouver Coastal Health · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will be investigating the effects of fesoterodine on autonomic dysreflexia (AD) in patients with spinal cord injuries (SCI). The goal of the study is to examine the effect of increasing daily use of fesoterodine on episodes of high blood pressure triggered by urinary bladder contractions.

Timeline

Start: 2016-02-25
Primary completion: 2019-01-31
Completion: 2019-01-31

Publications

Walter M, Ramirez AL, Lee AH, Rapoport D, Kavanagh A, Krassioukov AV. Protocol for a phase II, open-label exploratory study investigating the efficacy of fesoterodine for treatment of adult patients with spinal cord injury suffering from neurogenic detrusor overactivity for amelioration of autonomic dysreflexia. BMJ Open. 2018 Nov 21;8(11):e024084. doi: 10.1136/bmjopen-2018-024084.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fesoterodine	Other / unclassified	4 mg	Oral

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

Summary

Timeline

Publications

Drugs

Indications